Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

Creators: Bidard, François-Clément; Ychou, M.; Madic, J.; Saliou, A.; Bouche, O.; Rivoire, M.; Ghiringhelli, François; Francois, E.; Guimbaud, R.; Mineur, L.; Khemissa-Akouz, F.; Mazard, T.; Moussata, D.; Cacheux; Proudhon; Stern, M-H.; Pierga, J-Y.; Stanbury, T.; Thezenas, S.; Mariani, P.

Others:: Institut Curie [Paris]; UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM) ; CRLCC Val d'Aurelle - Paul Lamarque; Centre Hospitalier Universitaire de Reims (CHU Reims); Centre Léon Bérard [Lyon]; Lipides - Nutrition - Cancer (U866) (LNC) ; Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA); Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA); Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Centre Hospitalier Saint Jean de Perpignan; Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS) ; Hospices Civils de Lyon (HCL); Unité de génétique et biologie des cancers (U830) ; Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM); the European Society for Medical Oncology

Description

Background: We prospectively detected circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) levels in patients (pts) included in the PRODIGE14-ACCORD21-METHEP2 randomized phase II trial.Methods: The trial enrolled colorectal cancer pts with potentially resectable liver metastases & no prior treatment; the primary endpoint was the rate of R0/R1 liver metastases resection achieved by 1st line regimen (targeted therapies & bi- vs tri-chemotherapy; Ychou, ASCO 2016). Blood samples were collected at inclusion, after 1 month of therapy and before any liver metastases surgery. CTCs (CellSearch) & ctDNA (ddPCR, BioRad) were detected in an experienced laboratory (Inst. Curie).Results: 153 pts had at least one blood analysis. High CTC count (≥3 CTC/7.5ml) was detected in 25/132 pts (19%) at baseline and associated with synchronous...

Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

Description

Abstract

Abstract

Additional details